Literature DB >> 4057073

Pharmacological activity of the isomers of LY53857, potent and selective 5-HT2 receptor antagonists.

M L Cohen, K D Kurz, N R Mason, R W Fuller, G P Marzoni, W L Garbrecht.   

Abstract

LY53857 is an ergoline derivative that is a potent and selective antagonist at 5-HT2 receptors. The present study investigated the activities of the diastereomers of LY53857. The SS- and RR-isomers and the meso mixture of isomers of LY53857 all showed affinity for 5-HT2 receptors approximately 100-fold higher than for 5-HT1 receptors based on radiolabeled ligand binding studies in rat cortical membranes. Based on these binding data, the meso mixture of isomers was one-half as potent as the other two isomers. Consistent with the binding data, the SS- and RR-isomers and the meso mixture of isomers all showed high affinity as antagonists of 5-HT2 receptors in the rat jugular vein, with the meso mixture of isomers being slightly less potent than the other two isomers. Affinity of the isomers at alpha-1 and alpha-2 receptors was low. Approximately 100,000- and 2000-fold higher concentrations were required for antagonism of alpha-1 and alpha-2 receptors, respectively, relative to 5-HT2 receptors. A similar profile of selectivity was demonstrated for each of the isomers studied. These in vitro data were consistent with in vivo data showing the high i.v. and p.o. potency of all the isomers to antagonize the pressor response to i.v. administration of serotonin in pithed spontaneously hypertensive rats. As seen in vitro, the meso mixture of isomers was slightly less potent than the SS- and RR-isomers after p.o. administration in vivo.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4057073

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

Review 1.  The role of 5-hydroxytryptamine and 5-hydroxytryptaminergic mechanisms in hypertension.

Authors:  P A van Zwieten; G J Blauw; P van Brummelen
Journal:  Br J Clin Pharmacol       Date:  1990       Impact factor: 4.335

Review 2.  The role of serotonin in cardiovascular diseases and their treatment.

Authors:  P A van Zwieten; G J Blauw; P van Brummelen
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

3.  The influence of 5-hydroxytryptamine agonists and antagonists on identified sympathetic preganglionic neurones in the rat, in vivo.

Authors:  D I Lewis; J H Coote
Journal:  Br J Pharmacol       Date:  1990-04       Impact factor: 8.739

Review 4.  Pharmacological profile of antihypertensive drugs with serotonin receptor and alpha-adrenoceptor activity.

Authors:  P A van Zwieten; G J Blauw; P van Brummelen
Journal:  Drugs       Date:  1990       Impact factor: 9.546

5.  Central administration of 5-HT activates 5-HT1A receptors to cause sympathoexcitation and 5-HT2/5-HT1C receptors to release vasopressin in anaesthetized rats.

Authors:  I K Anderson; G R Martin; A G Ramage
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

6.  Role of protein kinase C in constrictor responses of the rat basilar artery in vivo.

Authors:  M A Murray; F M Faraci; D D Heistad
Journal:  J Physiol       Date:  1992-01       Impact factor: 5.182

7.  Effect of serotoninergic drugs on stress-induced hyperthermia (SIH) in mice.

Authors:  A Lecci; F Borsini; A Mancinelli; V D'Aranno; M A Stasi; G Volterra; A Meli
Journal:  J Neural Transm Gen Sect       Date:  1990

Review 8.  Different types of centrally acting antihypertensives and their targets in the central nervous system.

Authors:  P A van Zwieten; J P Chalmers
Journal:  Cardiovasc Drugs Ther       Date:  1994-12       Impact factor: 3.727

9.  Tandem regulation of phosphoinositide signaling and acute behavioral effects induced by antidepressant agents in rats.

Authors:  Kimberly R Tyeryar; Ashiwel S Undie
Journal:  Psychopharmacology (Berl)       Date:  2007-04-15       Impact factor: 4.415

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.